Precigen announced today the FDA approval of Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP), according to a news release . This is the first and only FDA-approved therapy for adults with RRP. A confirmatory clinical trial is not needed. Precigen will hold a conference call on August 18 at 8:00 am ET to provide additional details.

RRP is a rare and potentially life-threatening disease characterized by the growth of benign, wart-like growths called papilloma on the upper and lower respiratory tract, caused by specific types of human papillomavirus (HPV), specifically HPV 6 or HPV 11.

Approximately 27,000 adults in the United States suffer from RRP. Symptoms include hoarseness, chronic cough or breathing problems. It i

See Full Page